Dr. Elizabeth K. Lee discusses the RAINFOL-01 clinical trial evaluating treatment with Rina-S in advanced ovarian cancer.

AbbVie's Elahere has been shown to reduce the risk of death in patients with folate receptor-alpha (FRα) positive, platinum-resistant ovarian cancer by a third, reinforcing its blockbuster ...

The American multinational pharmaceutical company has strengthened its portfolio in recent years through several key acquisitions, adding significant growth assets such as the cancer drug Elahere ...

We recently published a list of the 10 High Growth Forever Dividend Stocks to Invest In. In this article, we are going to ...

It’s worth noting that BMS’ decision to exit the deal comes shortly after AbbVie secured full FDA approval for its FRα-directed ADC candidate – Elahere (mirvetuximab soravtansine ...

Four healthcare dividend stocks with significant upside potential and safe dividends look like outstanding investing ideas ...